Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Immunovant, Inc.

Get SEC filing alerts via email and in your feed for Immunovant, Inc.

IMVT

Immunovant, Inc.

About Immunovant, Inc.

Immunovant, Inc. is a clinical-stage biopharmaceutical company developing monoclonal antibodies targeting FcRn to treat autoimmune diseases. Its lead candidate, IMVT-1402, aims to reduce pathogenic IgG antibodies across multiple indications, including Graves' disease, myasthenia gravis, CIDP, and various dermatologic and rheumatologic conditions. The company focuses on innovative, targeted therapies with potential best-in-class efficacy, safety, and convenient self-administration for autoimmune patient populations worldwide.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Immunovant, Inc.

1
1
Immunovant, Inc. Immunovant Reports $505.6 Million Net Loss for Fiscal Year Ended March 31, 2026

Via official filing (AI summary) | 15 days ago | 0 comments

2
1
Immunovant, Inc. Immunovant Reports $110.6 Million Net Loss, Completes $543.6 Million Stock Offering

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
Immunovant, Inc. Immunovant Reports $126.5 Million Net Loss in Q2 Fiscal 2026

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Immunovant, Inc. Immunovant Reports $120.6 Million Net Loss and Increased Operating Expenses for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Immunovant, Inc. Immunovant Reports Fiscal Year 2025 Results and Advances Clinical Pipeline

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Immunovant, Inc. Immunovant Reports $111.1 Million Net Loss in Latest Quarter Amid Rising Operating Expenses

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Immunovant, Inc. Immunovant Reports Significant Financial Decline, Net Loss, and Plans for Future Fundraising

Via official filing (AI summary) | over 1 year ago | 0 comments